Richard - Premier Clinical Research

CURRICULUM VITAE

April 2011

NAME AND ADDRESS: Richard G. Gower, M. D., FACAAI, FAAAAI, FACP

823 W. 7 th Avenue

Spokane, WA 99204

Phone: 509 879 4523 cell

Email: rgower@marycliffallergy.com

PROFESSIONAL STATUS

Current: Marycliff Allergy Specialists, PS, 2006-Present

Allergy/Asthma/Clinical Immunology

Clinical Associate Professor of Medicine, University of WA

823 West 7 th Avenue

Spokane, WA 99204

Phone: (509) 838 3655

Fax: (509) 838 1952

Email: rgower@marycliffallergy.com

.

Sub Investigator for:

Pulmonary and Research Associates

104 West Fifth Avenue, Suite 400 West

Spokane, WA 99204

Past: Partner-Rockwood Clinic, 1977-2006

400 East 5 th Avenue

Spokane, WA 99202

Phone: (509) 838 2531

UNIVERSITIES ATTENDED:

Wabash College, Crawfordsville, Indiana, 1964-1968

Major: Biology

Minor: Chemistry

A. B. Degree Cum Laude

University of Colorado School of Medicine,

Denver, Colorado, 1968-1972

Doctor of Medicine Degree, May 24, 1972

PROFESSIONAL TRAINING:

Externship: Radiology. General Rose Memorial Hospital,

Denver, Colorado, summer 1970

Rural Preceptorship: General Practice. Craig, Colorado, summer 1971

Internship: Straight Medicine. University of Miami Affiliated

Hospitals, Miami, Florida. Hospitals: Jackson Memorial,

Veterans Administration, National Children's Cardiac

Hospital, July 1972 - June 1973

Residency: Internal Medicine. University of Miami Affiliated Hospitals,

Miami, Florida. Hospitals: Jackson Memorial,

Veteran's Administration, Mt. Sinai, July 1973 - June 1975

Fellowship: Allergy and Clinical Immunology, Vasculitis.

University of Colorado Medical Center

Hospitals: Colorado General, Veterans Administration,

Denver General, National Jewish Hospital, Fitzsimmons Army

Hospital, Children's Asthma Research Institute and Hospital,

July 1975 - June 1977

EXTRACURRICULAR ACADEMIC TRAINING:

Wabash College:

Laboratory Instructor, invertebrate zoology, fall semester 1966

Laboratory Instructor, morphogenesis of vertebrates, spring semester, 1967

Faculty Instructor, general biology, 1967 - 1968

Medical School:

Research in radiation and health physics, Department of

Radiology, University of Colorado Medical School, summer

1968

Research fellowship grant for work in tagging red blood cells with chromium-51 and developing a liquid scintillation counting technique for counting the tagged globin portion of the hemoglobin molecule, Department of Radiology, University of Colorado Medical Center, summer 1969

Morgue diener, Department of Pathology, General Rose Memorial

Hospital, Denver, Colorado, summer 1970

Richard G. Gower, M.D. 2

Internship-Residency:

Emergency Room Work (extracurricular):

Memorial Hospital, Hollywood, Florida, 1973, 1974, 1975

South Miami Hospital, Miami, Florida, 1974, 1975

Lauderdale Lakes Hospital, Ft. Lauderdale, Florida, 1974, 1975

Fellowship:

Primary coordinator of an ongoing vasculitis study group

Attending physician in Colorado General's Allergy Clinic, 1976-1977

Emergency Room Work (extracurricular), 1975-1977

HONORS AND AWARDS:

Wabash College

College Scholarship, 1964 - 1966

Alfred B. Sloan Scholar, 1966 - 1968

President, Campus Center Board, 1967 - 1968

Phi Beta Kappa, 1968

Medical School

Glen E. Cheley Scholarship, 1968 - 1969

Health Professions Scholarship, 1968 - 1969

Awarded certificate from American College of Surgeons, Colorado

Trauma Committee, Immediate Emergency Care Course, 1969

Medical student representative for the basic sciences from the

University of Colorado School of Medicine to National Student

Research Forum (SAMA-UTMB) at Galveston, Texas, April 1969

Medical Practice

The National Registry of Who’s Who, Life Member, 2000 edition

Medical Practice

Recognized in the “Guide to America’s Top Physicians” by SLD Industries, Consumers

Research Council of America, 2009

CERTIFICATION:

National Board of Medical Examiners Parts 1, 2, and 3 (Diplomate)

Florida State Boards

Colorado Basic Science Boards

American Board of Internal Medicine - Board Certified 1975

(Diplomate)

American Board of Allergy and Immunology - Board Certified 1977

(Diplomate)

American College of Allergy, Asthma, and Immunology – Fellow, 1986


American College of Physicians – Fellow, 2006

STATE LICENSES:

Washington, Florida (inactive), Colorado (inactive)

HOSPITAL STAFF PRIVILEGES:

Sacred Heart Medical Center, Spokane, Washington

Deaconess Medical Center, Spokane, Washington

SOCIETY AFFILIATIONS:

American College Allergy/Asthma/Immunology (Fellow)

American Academy of Allergy/Asthma/immunology (Fellow)

American College of Physicians (Fellow)

American Lung Association

American Medical Association

Association of Allergists from India

Association of Pharmaceutical and Physician Investigators

Intermountain West Allergy Association

Northwest Rheumatism Society

Phi Beta Kappa

Spokane Society of Internal Medicine

Spokane County Medical Society

Washington State Medical Association

Washington State Society of Allergy/Immunology

Washington State Society of Internal Medicine

Washington State Thoracic Society

Western Society of Allergy, Asthma and Immunology

PROFESSIONAL APPOINTMENTS:

Attending Physician, Sacred Heart Medical Center,

1977 - Present

Attending Physician, Deaconess Medical Center,

1977 - Present

Attending Physician, St. Luke's Hospital, 1977 - 1993

Chairman, Department of Medicine, St. Luke's Hospital,

1979 - 1981 and 1988 - 1990

Trustee, St. Luke's Hospital, 1981 - 1982


TEACHING AFFILIATIONS

Clinical Associate Professor of Medicine, University of Washington School of

Medicine - attending/lecturer for Internal Medicine Residency at Sacred

Heart Hospital and Deaconess Hospital in Spokane, Washington

COMMUNITY AND PROFESSIONAL SERVICES:

Past President, American College of Allergy, Asthma, and Immunology,

2010-2011

Immediate Past President, American College of Allergy, Asthma, and Immunology,

2009-2010

President, American College of Allergy, Asthma, and Immunology, 2008-2009

President-Elect, American College of Allergy, Asthma, and Immunology, 2007-2008

Vice President, American College of Allergy, Asthma, and Immunology, 2006-2007

Treasurer, American College of Allergy, Asthma, and Immunology,

2003-2006; Treasurer, ACAAAI Foundation, 2003-2006

Executive Committee, American College of Allergy, Asthma, and Immunology,

2000-2002 and 2003-2008.

Member, ACAAI Investment Oversight Committee, 2003-2008

Regent, Board of Regents, American College of Allergy, Asthma, and

Immunology, 1999-2002

Chairman, Health System Reform Committee, American Society of Internal Medicine, Washington, D. C., 1993 - 1995

Member 1987 – 1995

Speaker, House of Delegates, American College of Allergy, Asthma, and

Immunology, 1997-1999; Vice-Speaker, 1994-1997

Chairman, American College of Allergy, Asthma, and Immunology Task

Force on Education of Fellows in Training and Primary Care, 1998-2000

Member, HEDIS Task Force, American College of Allergy, Asthma, and

Immunology, 2004-present


Member, American College of Allergy, Asthma, and Immunology CME

Committee, 1997-2000; Annual Program Committee, 1997-1998

Chairman, JCAAI Membership Recruitment Committee, 2002-2006

Member, Joint Council of Allergy, Asthma and Immunology, 2001-2006; 2007-2008

President, Western Society of Allergy, Asthma, and Immunology,

1997-1998. Immediate Past President, 1998-1999, Executive

Council, 1993-2000

President, Intermountain West Allergy Association, 2000-2001;

Vice-President, 1997-2000, Program Chairman, 1998, Immediate Past

President, 2001-2002

Chairman, Managed Care Committee, American College of

Allergy, Asthma, and Immunology, 2001-2002. Member, 1994-2002

Member, ACAAI Managed Care Strike Force, 1994-1995

Chairman, Professional Allergy/Immunology Education Committee, ACAAI,

2001-2004; member, 2000-2006

Chairman, ACAAI Public Relations Network, 2002-2005, Vice-Chairman, 2000-2002;

Member, 1993-present

Program Co-Chairman, American College of Allergy, Asthma and

Immunology, “Meeting the Challenge of Change”, Keystone, Colorado,

July 16-18, 1999

Member, Judicial Council of Washington State Medical Association, 1995-1998

Member, Membership Recruitment Committee, American College of Allergy,

Asthma, and Immunology, 1998-2005

Member, Professional Education Council, ACAAI, 2001-2005

Consultant: 1. International Asthma Advisory Board, Schering-Plough

International, Inc.; September 5-7, 1996, Stockholm, Sweden

2. National Asthma Advisory Board, Astra Pharmaceuticals,

August 22-25, 1996, Colorado Springs, Colorado.

3. Biaxin Advisory Board, Abbott Laboratories, September

27-29, 1996, Rancho Mirage, California.

4. Asthma Management Guidelines, Healthplus of Washington,

September, 1996.


Consultant: (cont’d)

5. American Lung Association of Washington, Washington

State Asthma Project, Professional Education Task Force,

June 1997 - Present.

6. Regional Pediatric Asthma Advisory Board, Merck, July 24-26,

1997, Seattle, Washington

7. Asthma Management Guidelines for Children, Blue Cross of

Washington, November, 1997.

8. Asthma Disease Management Program, Group Health

Northwest, December 18, 1997.

9. Allergic Disease Management, Key Pharmaceuticals, June

18-20, 1998, San Francisco, California

10. Asthma Disease Management, Key Pharmaceuticals,

February 12-15, 1998, New York, New York

11. Asthma Disease Management, Rhone-Poulenc Rorer,

February 19-22, 1998, Tampa, Florida

12. Editorial Board, Key Pharmaceuticals, Asmanex

Twisthaler: A New Inhaled Corticosteroid for the

Treatment of Asthma: June 3-4, 1999, Chicago, Ill.

August 25-27, 1999, San Francisco, California

13. Allergic Rhinitis and Sinusitis Management Guidelines,

Premera of Washington, January 2001

14. National Allergist Advisory Board, Aventis,

2001, Coeur d’Alene, Idaho, 2002, Vaancouver, BC, 2002,

Kohler, Wisconsin, 2003, San Diego, CA, 2005

15. Novartis Ophthalmic, Key Biscayne, Florida, February 8-10 2002

16. Respiratory Advisory Board Meeting, IVAX Laboratories,

Miami, Florida, February 15-17, 2002

17. ABRS National Consultant Meeting, Scottsdale, AZ, Dec. 2004,

Sanofi Aventis

18.

RESP Council, San Diego, CA, May 26-27 2005 and Dec. 16, 2005

19.

ALCON Allergic Foundation Board, June 17, 2005, Chicago, Ill.

President, Inland Empire Allergy Forum, 1993-1999

Vice-President, Rockwood Clinic Medical Foundation (Research),

1988 –1998

Board of Directors, Inland Northwest Blood Center, 1993 - 1998

Secretary-Treasurer, 1997-1998

President, Washington State Society of Internal Medicine, 1986-1987

Executive Council: 1984 - 1987; 1994 -1999

Member, Washington State Asthma Project, 1997-2002


Planning and Building Committee, New Rockwood Clinic Multispecialty

Center, 1984-1987

Medical Director, Regional Systemic Lupus Erythematosus Support

Group, 1977 - 1991. Medical Advisor, 1977-1997

Specialty Advisory Council, Medical Service Corporation,

1993 - 2005

Delegate, Washington State Medical Association, 1987, 1990, 1993,

1994, 1997

Member, American College of Allergy, Asthma, and Immunology

Public Relations Program, 1990 - Present

Member, Public Awareness and Community Education Committee

Washington State Medical Association, 1987 - 1995

Program Chairman, Washington State Medical Association Annual

Meeting, Symposium on Allergy/Immunology, Spokane, Washington,

September 1986 and 1990.

Program Chairman, Washington State Medical Association/

Washington State Society of Internal Medicine Symposium,

Tacoma, Washington, September 18, 1987

Program Chairman, Rockwood Clinic Fall Medical Symposia,

1987 - 1990

Program Coordinator, Washington State Medical Association/

Washington Society of Internal Medicine Symposium on "The

Future of Medicine", Spokane, Washington, May 15, 1993

Initiated and implemented Immune Deficiency Support Group,

Spokane, Washington 1992

Initiated and implemented Rockwood Clinic/Hutton Elementary

School "Partners in Business Program," Spokane, Washington,1987 - 1992

Initiated and implemented Foreign Travel and Immunization Clinic,

Spokane, Washington, 1983.

Volunteer "Parent of the Year," Hutton Elementary School, 1992

Member, Independent Data Safety Monitoring Board, ISTA Pharmaceuticals, 2010

Editorial Board of Angioedema Journal, 2009-2011


1.

PUBLICATIONS:

"Ultraviolet-induced Changes in Residual Thermoluminescence from

Gamma-irradiated Lithium Fluoride." Richard G. Gower,

William R. Hendee, and Geoffrey S. Ibbott, Health Physics,

Vol. 17, 1969, pp. 607-611.

The above paper presented at:

National Student Research Forum at Galveston, Texas, April 1969

Southwestern and Rocky Mountain Division, American Association for the Advancement of Science, Colorado Springs, Colorado,

May 1969

2.

4.

Rocky Mountain Radiological Society, Midsummer Conference,

Denver, Colorado, summer 1969

"Leukocytoclastic Vasculitis - A Sequential Study of

Immunoreactants and Cellular Reactants After Histamine

Injection." Richard G. Gower, W. Mitchell Sams, E. George

Thorne, Peter F. Kohler, and Henry N. Claman, Journal of

Investigative Dermatology, 1977.

Paper presented at the American Academy of Dermatology,

Chicago, Illinois, December 1976 by Dr. Gower.

3. "Small Vessel Vasculitis Associated with Hepatitis B Surface

Antigen," Richard G. Gower, William F. Sausker, Peter F.

Kohler, E. George Thorne, Rawle M. McIntosh, Journal of

Allergy/Clinical Immunology, Vol. 62, No. 4, October 1978.

Paper presented at the American Congress of Allergy, New York

City, New York, March 1977 by Dr. Gower.

"Cerebral Vasculitis Associated with Pheochromocytoma," two case reports by Richard G. Gower, M.D., in Dr. William M.

Manger's textbook, Clinical and Experimental Pheochromocytoma, second edition, Chapter 7, pp. 335-339, Blackwell Science 1996.

Paper presented by Dr. Gower at:

Washington State Allergy Society Annual Meeting

Alderbrook, Washington, May 2, 1992.

Annual Aspen Allergy Conference, Aspen, Colorado, July 23, 1992.

American College of Allergy and Immunology, Chicago, Illinois,

November 14 - 16, 1992


5.

.

Northwest Rheumatism Society Annual Meeting, Seattle,

Washington, April 30, 1993.

British Society of Allergy and Clinical Immunology,

Nottingham, England, August 2, 1993.

Western Society of Allergy and Immunology, Kona, Hawaii,

January 23 - 26, 1994.

“Hypothalamic-Pituitary-Adrenal Axis Function During Treatment of Pediatric and Adolescent Asthma with Beclomethasone Dipropionate or Fluticasone

Propionate”, Advances in Therapy, March/April 1997, Volume 14, No. 2.

6. “Inhaled Mometasone Furoate Reduces Oral Prednisone Requirements While

Improving Respiratory Function and Health-Related Quality of Life in Patients

With Severe Persistent Asthma”: Journal of Allergy and Clinical Immunology,

November 2000, pp. 852-860

7. “Insurance Coverage for H1 Antihistamines: Implications for Quality Health Care and Public Safety”. Position Statement of the AAAAI, ACAAI, and JCAAI, co-author,

November 18, 2002.

8. “Reduction in Oral Corticosteriod Use with Mometasone Furoate Dry Powder

Inhaler Improves Health-Related Quality of Life in Patients With Severe

Persistent Asthma”, Jordana Schmier, Nancy Kline Leidy, and Richard G.

Gower, Jnl. Of Asthma, vol 40, No. 4, pp 383-393, 2003

Paper Presented (poster) at European Respiratory Society, Stockholm, Sweden,

September 2002, by Dr. Gower

Paper Presented (poster) at Western Society of Allergy, Asthma, and Immunology,

Kona, Hawaii, January 2003 by Dr. Gower

9. “Once-daily ciclesonide is effective and well-tolerated in the treatment of Adult and

Adolescent patients with mild-to-moderate Asthma”. Poster presentation, March

2005, AAAAI

10. “Eradication of common pathogens at Days 2, 3, and 4 of moxifloxacin therapy in

patients with acute bacterial sinusitis”, BMC Ear, Nose and Throat Journal, website as “Provisional PDF”, 2006, 6:8

11. “A multi-site study evaluating patient perceptions of Olapatadine 0.2% in patients with allergic conjunctivitis.” Poster presentation, Western Society of Allergy, Asthma, and

Immunology, January 2008.

12. “Sub-lingual Immunotherapy: WAO Position Paper 2009.”


13. “How GARD is integrating the WHO Noncommunicable Diseases action plan and

NCDnet: (Noncommunicable Disease Network)” 2009

14. “Clinical Presentation, Diagnosis, and Treatment of Hereditary Angioedema: An

Overview”. Clinical Cornerstone. Focus on Angioedema. Vol. 10, Supplement 1. 2011

15. “Current Medical Management of Hereditary Angioedema: Results From a Large Survey of U.S. Physicians. Annals of Allergy, Asthma & Immunology.” 2011

16. “Hereditary Angioedema Caused by C1-Esterase Inhibitor Deficiency: A Literature-Based

Analysis and Clinical Commentary on Prophylaxis Treatment Strategies.” World Allergy

Organization Journal. 2011 (In Process)

17. Hereditary Angioedema Treatment: Consensus Paper. World Allergy Organization Journal.

2011 (In Process)

BOOK REVIEW:

Frozen Tears. John Strimas, M.D., published in Annals of Allergy, vol. 94, May 2005

SCIENTIFIC PUBLICATION REVIEW:

Journal reviewer for Annals of Allergy. 1995-present

Journal reviewer for Allergy and Asthma Proceedings. 2003-2007

Editorial Board of Angioedema Journal, 2009-present

“Management of Allergic and Nonallergic Rhinitis”, Evidence Report, New England

Medical Center Evidence-based Practice Center, 2001

“Rhinitis Severity Assessment” manuscript, supplement to “Rhinitis Parameters” 1998,

Joint Task Force on Practice Parameters, 2002

Device Selection and Outcomes of Aerosol Therapy:

ACCP/ACAAI Evidence-Based Guidelines

Dolovich, MB et al. February, 2004

“Asthma Management and the Allergist: Better Outcomes at

Lower Cost”, Blue Book, March 2003

“A Comparison of Delivery Devices: Small Volume Nebulizers and Metered Dose Inhalers”. B. Chipps et al, January 2004

“Sinusitis Practice Parameters”. ACAAI, S. Spector et al, 2004


“When is prophylaxis for hereditary angioedema necessary?”. Annals of Allergy,

Craig et.al. 2009

“Sub-Lingual Immunotherapy WAO Position Paper 2009”. WAO Position Paper,

Canonica et. al. 2009

“Hereditary Angioedema Caused by C1-Esterase Inhibitor Deficiency: A Literature-Based

Analysis and Clinical Commentary on Prophylaxis Treatment Strategies”.

Gower, et al. WAO Journal. 2011

“Current medical management of hereditary angioedema: results from a large survey of

US physicians”. Riedl et. al. 2011. Annals of Allergy 2011

“Clinical Presentation, Diagnosis, and Treatment of Hereditary Angioedema: An

Overview”. R. Gower and E.S. Levitch. Clinical Cornerstone Supplement. 2011

“Evidence-Based recommendations for the Therapeutic Management of angioedema due to hereditary C1- inhibitor deficiency. (a consensus report of international working group). Cicardi, et. al. WAO 2011. In process.


8.

7.

6.

5.

PRESENTATIONS:

1. "Treatment of Stinging Insect Sensitive Patients with Hymenoptera

Venom Desensitization."

Presentation on April 24, 1981, at Snake River Medical Forum,

Lewiston, Idaho.

2. "Fiberoptic Rhinopharyngolaryngoscopy in the Practice of Clinical

Immunology: A study of 80 Patients."

Presentation in May 1986 at annual Washington State Allergy

Society Meeting, Ocean Shores, Washington.

3. "Systemic Lupus Erythematosus."

Presentation in September 1986 at Washington State Medical

Association annual meeting, Spokane, Washington.

4. "Are Immunological Tests Worthwhile?"

Presentation on November 14, 1987, at Rockwood Clinic Fall

Medical Symposium, Spokane, Washington.

Presentation on March 24, 1995, at annual Montana Big Sky

Pulmonary Conference, Bozeman, Montana.

Presentation on September 21, 2001, at Grand Rounds Conference,

Bozeman, Montana

"Diagnosis and Treatment of Asthma."

Presentation on May 20, 1988, at Snake River Medical Forum,

Lewiston, Idaho

Presentation on February 25, 1989, at annual Spokane Society of

Internal Medicine Symposium, Spokane, Washington.

"Atopic Dermatitis."

Presentation on November 4, 1989, at Rockwood Clinic Fall

Medical Symposium, Spokane, Washington.

"Asthma, the Nocturnal Disease."

Presentation on October 12, 1992, at Medical Grand Rounds,

Kalispell, Montana

"Asthma Therapeutics: The Controversies Surrounding

Bronchodilators and Anti-inflammatory Medicines."

Presentation on February 17, 1993, for the American Lung

Association of Washington, Spokane, Washington.


9. "Living with Allergies."

Presentation on March 3, 1993, to general public for Rockwood

Clinic's "Health Talks" series in Spokane, Washington.

10. "The Role of Nasal Steroids and Antihistamines in Allergic

Rhinitis"

Presentation on March 17, 1993, for Idaho Pharmacists in

Pullman, Washington.

Presentation on March 24, 2001 to regional physicians in Seattle, WA.

11. "Asthma and Emphysema - Myths and Facts."

Presentation on April 15, 1993, for American Lung Association of

Washington in Spokane, Washington.

12. "Advances in the Treatment of Allergic Rhinitis."

Presentation on July 24, 1993, in Coeur d'Alene, Idaho.

Presentation on September 13, 2001, in Lewiston, Idaho.

13. "Assessment and Treatment Costs in COPD: Cost Effective Care

Under Capitation."

Presentations on November 4, 1993, and February 3, 1994, in

Spokane, Washington.

Presentation on March 25, 1995, at annual Montana Big Sky

Pulmonary Conference, Bozeman, Montana.

.

14. "Immunoglobulin Therapy for Immunodeficiency States."

Presentation on March 21, 1994, for University of Washington

School of Medicine Sub-Specialty Conference, Spokane, Washington.

Presentation on February 28, 1997, for Medical Grand Rounds at Providence

Hospital, Anchorage, Alaska

15. "Hay Fever and Sinus Problems."

Presentation on April 14, 1994, and January 15, 1997,to general public for

Rockwood Clinic's "Health Talks" series in Spokane, Washington.

16. "Allergic Rhinitis and Sinusitis."

Presentation on May 19, 1994, for North Idaho Medical Association, Lewiston, Id.

17. "Immunizations and Medications In Lupus Patients Traveling Abroad."

Presentation on May 20, 1994, for the American Lupus Society in Spokane, Washington.

18. "Challenging Cases in Allergy and Immunology."

Moderator and Discussant on September 21, 1994, in Coeur d'Alene, Idaho.


19. "Vasculitis and Autoimmune Disease States."

Presentation on October 8, 1994, for the American Lupus Society in Spokane, Washington.

20. "Medications and Asthma." Washington Lung Association.

Presentation on October 26, 1994, for Washington Lung Association,


21. "Primary Care Issues in the Management of Asthma."

Teleconference presentations to physicians and staff in:

Toccoa, Georgia, on December 6, 1994

Inglewood, California, on December 8, 1994

Lewiston, Idaho, on February 7, 1995

Olympia, Washington on February 10, 1995

Great Falls, Montana, on February 15, 1995

Sparks, Nevada, on March 14, 1995

Tacoma, Washington, on March 21, 1995

Seattle, Washington, on March 21, 1995

Bellevue, Washington, on March 22, 1995

Spokane, Washington on March 29, 1995

Spokane, Washington, on March 30, 1995

Seattle, Washington on April 6, 1995

Belfair, Washington, on April 18,1995

Vancouver, Washington, on May 4, 1995

Coeur D'Alene, Idaho, on July 21, 1995

Spokane, Washington, on August 30, 1995

Citrus Heights, California, on November 29, 1995

22. "Treatment Options for Upper and Lower Respiratory Tract Infections in Clinical

Practice” Presentations on:

December 12, 1994, for community physicians in Missoula, Mt.

April 25, 1995, for physicians' assistants in Spokane, Washington

December 6, 1995, for community physicians in Spokane, Wa.

March 27, 1996, for regional physicians in Coeur d'Alene, Idaho.

May 29, 1996, for regional physicians in Moses Lake, Wa.

October 16, 1996, for regional physicians in Missoula, Mt.

October 24, 1996, for community physicians in Spokane, Wa.

October 30, 1996, for community physicans in Spokane, Wa.

November 14, 1996, for regional physicians in Coeur d'Alene, Id.

December 9, 1996, for regional physicians in Moses Lake, Wa.

December 18, 1996, for regional physicians in Whitefish, Montana

February 1, 1997, for regional physicians in Richland, Wa.

February 27, 1997, for regional physicians in Fairbanks, Alaska

February 28, 1997, for regional physicians in Anchorage, Alaska

23. "Itches, Ouches, and Rashes."

Presentation May 10, 1995, to public for Rockwood Clinic's "Health Talks"

series in Spokane, Washington.


24. "The Role of Theophylline in Asthma Therapy in 1995."

Presentation June 14, 1995, for community physicians in Spokane, Washington

25. "An Update in the Treatment Options for Sinusitis."

Presentation July 29, 1995, for regional physicians in Spokane, Washington.

26. "Hypersensitivity Vasculitis: Diagnosis, Management, and Systemic Associations"

Presentation September 29, 1995, for Washington State Medical Association annual meeting, Spokane, Washington.

27. "Antiviral Therapy Update."

Presentations October 25, 1995, and January 16, 1996, for regional physicians in Spokane, Washington.

28. "Treatment Modalities in Allergic Rhinitis."

Presentation March 6, 1996, for regional physicians in Plummer, Idaho.

29. "Living With Lupus."

Presentation March 13, 1996, for community patients and family members in


30. "Allergic Rhinitis: The Association with Sinusitis and Otitis Media."

Presentation April 24, 1996, for regional physicians in Coeur d'Alene, Idaho.

31. "Does Theophylline Still Have a Role in Asthma Management?"

Presentation May 1, 1996, for regional physicians in Great Falls, Montana.

32. "Diagnosis and Management of Asthma."

Presentation May 18, 1996, for Washington State Society of Medical

Assistants annual meeting, Spokane, Washington.

33. "Management Guidelines for Allergic Rhinitis."

Presentation June 7, 1996, for Snake River Forum annual meeting in

Lewiston, Idaho.

34. "Delivery Devices and Oral Inhaled Corticosteroids: Clinical Update in Asthma

Management."

Teleconference presentations to physicians and staff June 19, 26, July

3, 10, 17, September 11, and December 12, 18, 1996.

35. "Snifflin', Sneezin', and Scratchin'"

Presentation September 3, 1996, for Spokane Valley Hospital physicians,



36. "Winter Asthma and Allergy"

Presentation October 10, 1996, for community physicians in Spokane, Wa.

37. "Advancements in Asthma Treatments: Newer Corticosteroids and Delivery Systems."

Presentation November 6, 1996, for community pulmonologists in Spokane,

Washington.

38. "The Socioeconomic Impact of Allergic Rhinitis/Sinusitis"

Presentation December 10, 1996 for regional nurse practitioners in Spokane,

Washington.

39. "Medical Implications of Urticaria/Angioedema"

Presentation December 23, 1996, for University of Washington housestaff and community physicians in Spokane, Washington.

40. “Allergic Rhinitis: It’s Clinical and Economic Impact”

Presentation March 4, 1997, for regional physicians in Walla Walla, Wa., and Yakima, Wa.

41. “The Changing Role of Anti-Inflammatory Therapy in Asthma”

Presentation March 22, 1997, for community physicians in Seattle, Wa.

42. “Asthma Overview and Treatment Guidelines”

Presentation March 27, 1997, for community physicians in Spokane, Wa.

43. “The Association of Allergic Rhinitis and Sinusitis”

Presentation April 3, 1997, for regional physicians in Kennewick, Wa.

44. “The Role of Leukotriene Modifiers in the Treatment of Asthma”

Presentation April 15, 1997, for regional physicians in Walla Walla, Wa.

Presentation December 6, 2001, for regional physicians in Kennewick, Wa.

45. “New Therapies and Delivery Systems for Asthma”

Presentation April 24, 1997, for regional physicians in Spokane, Wa.

46. “Breathe Easy: Asthma Update”

Healthtalks Community Education Seminar, May 14, 1997, Spokane, Wa.

47. “Physical, Social, and Economic Impact of Allergic Rhinitis”

Presentation May 28, 1997, for regional physicians in Coeur d’Alene, Id.

48. “ New Guidelines for the Diagnosis and Management of Asthma”

Presentation August 24, 1997, for regional physicians in Portland,

Oregon


49. “The Association of Allergic Rhinitis, Asthma, and COPD”

Presentation August 27, 1997, for local physicians in Spokane, Wa.

50. “The Allergy-Asthma Link”

Presentation September 4, 1997, for regional physicians in Boise, Id.

Presentation March 18, 1999, for regional physicians in St. Maries, Id.

Presentation April 16, 1999, for Lovelace Clinic Grand Rounds,

Albuquerque, New Mexico.

51. “Significance and Treatment of Allergic Rhinitis”

Teleconference presentation on September 25, 1997, for regional physicians

52. “Immunologic Tests in Allergy/Asthma/Immunology”

Presentation September 26, 1997, at Washington State Medical Association in Yakima, Wa.

53. “Allergy Awareness in the Pediatric Population”

Presentation October 15, 1997, for regional pharmacists in Pullman, Wa.

54. “Treating Asthma in a Managed Care Environment”

Presentation November 15, 1997, for regional physicians at Regional Consultants’

Meeting on Asthma in Snoqualmie, Wa. Moderator of meeting.

55. “Oral Inhaled Corticosteriod Therapy as the Cornerstone of Treatment in Persistent

Asthma”

Teleconference presentations to western regional physicians October 8, 21, 23,

28, 1997 and November 4, 20, 1997.

56. “The Role of Leukotriene Modifiers in the Treatment of Asthma”

Presentation November 21, 1997 for regional physicians in Yakima, Wa.

Presentation December 4, 1997, for regional physicians in Pasco, Wa.

57. “Setting Sights on New Asthma Therapies and Delivery Systems”

Presentation December 6, 1997, for local physicians in Spokane, Wa.

58. “Resistance in Respiratory Tract Infections”


59. “Antiviral Update”


60. “Update in Allergic Rhinitis”

Presentation December 16, 1997, for regional physicians in Spokane, Wa.

61. “Update on Allergic Rhinitis and Inhaled Steroids”

Presentation December 20, 1997, for regional physicians in Seattle, Wa.


62. “Asthma/Allergy Link”

Presentation January 16, 1998 for regional physicians in Honolulu, Hi.

Presentation October 22, 1998 for regional physicians in Anchorage, AK.

Presentation December 14, 2005, for regional physicians in Portland, Or.

63. “Oral Corticosteroids in the Treatment of Asthma”

Presentation January 28, 1998 to regional pharmacists in Coeur d’Alene, Id.

64. “New Asthma Therapies (Leukotrienes): Effectively Control Your Patients With

Asthma”

Presentation March 17, 1998 to Northwest Academy of Family Practice

Annual Meeting in Spokane, Washington

65. “Inhaled Bronchial Steriods: Delivery, Proof in 3-D”

Presentation March 22, 1998 to regional physicians in Spokane, Wa.

66. “The Role of Leukotriene Inhibitors in the Management of Asthma”

Presentation April 15, 1998 for regional physicians’ Grand Rounds in Lewiston, Idaho

67. “What’s New in the Treatment of Allergic Rhinitis”

Presentation May 5, 1998, to regional physicians, Great Falls, Mt.

68. “Children and Asthma”

Presentation May 6, 1998 for Community Health Education and

Resources Meeting, Spokane, Washington

69. “Management of Allergic Rhinitis”

Presentation July 15, 1998, to regional physicians in Coeur d’Alene, Id.

Presentation June 2, 2001, to regional physicians in Seattle, Wa.

Presentation May 18, 2005, to regional physicians in Coeur d’ Alene, Id.

70. “Cornerstones of Asthma Treatment (New NIH Guidelines)”

Presentation September 26, 1998, at the Northwest Society of Allergy

Nurses’ Annual Conference, Otter Bay, Oregon

71. “Allergic Rhinitis”

Presentation October 23, 1998, at Alaska Regional Grand Rounds,

Anchorage, Alaska

72. “Managing Adult Asthma: A Dialogue on Current Issues and Options”

Presentation April 30, 1999, to regional physicians at the Primary

Care Update 16th Annual Conference, Spokane, Washington


73. “Managing Asthma and Issues in Drug Delivery”

Presentation May 6, 1999 to regional physicians in Missoula, Montana

Presentation August 8, 1999, to regional physicians in Seattle, Wash.

Presentation August 10, 1999 to regional physicians in Pasco, Wash.

Presentation August 14, 1999 to regional physicians in Seattle, Wash.

Presentation September 18, 1999, to regional physicians in Seattle, Wash.

Presentation December 11, 1999, to regional physicians in Sandpoint, Idaho

74. “Treatment of Allergic Rhinitis and Sinusitis in the 90’s”

Presentation July 20, 1999, to regional physicians in Carlsbad, California

75. “Efficacy of Mometasone Furoate in Patients with Mild to Moderate Asthma:

Once-Daily vs. Twice-Daily Dosing”

Presentation August 28, 1999 to national mometasone furoate investigors’ meeting, San Francisco, California


Presentation September 15, 1999, to regional physicians in Post Falls, Id.

77. “The Role of Leukotriene Antagonists in Asthma Management”

Presentation September 16, 1999, Lewiston, Idaho.

Presentation September 17, 1999 Coeur d’Alene, Idaho

Presentation April 19, 2001, Lewiston, Idaho

Presentation June 19, 2001, Boise, Idaho

Presentation June 12, 2002, Lewiston, Idaho

Presentation November 8, 2002, Hermiston, Oregon

Presentation December 10, 2002, Yakima, Washington

78. Mometasone Faculty Consensus Speaker’s Bureau:

“Grand Rounds in Asthma Management”, presentations October 23, 24, 1999 at

. national meeting in Vancouver, British Columbia.

“Asthma Tutorial Workshops”, panelist/moderator, October 30, 31, 1999 at national meeting in Scottsdale, Arizona

79. “Treatment Options in Rhinosinusitis”

Presentation February 18, 2000, to regional physicians in San Diego, Ca

Presentation March 4, 2000, to regional physicians in Sandpoint, Id.

Presentation March 22, 2000, to regional physicans in Richland, Wa.

Presentation April 19, 2000, to regional pharmacists in Pullman, Wa.

Presentation April 20, 2000, to regional physicians in Avondale, Id.

Presentation July 15, 2000, to regional physicians in Kellogg, Id.

Presentation February 23, 2001, to regional physicians in Great Falls, Mt.

Presentation June 7, 2001, at the 24th Annual Snake River Medical Forum,

Lewiston, Idaho


80. “Delivery Systems in the Treatment of Asthma”, ,

Presentation April 12, 2000, to regional physicians in Lewiston, Id.

81. “Oral Inhaled Corticosteroids in the Treatment of Asthma”

Presentation May 9, 2000, to regional physicians in Coeur d’Alene, Id.

82. “CDC Guidelines for Treatment of Respiratory Infections”

Presentation December 20, 2000, to regional physicians in Coeur d’Alene, Id.

83. “The Role of Combination Therapy in the Treatment of Asthma”

Presentation February 6, 2001, Lewiston, Idaho

Presentation February 28, 2001, Pullman, Washington


Presentation July 26, 2001, Tacoma, Washington

Presentation March 16, 2002 at Alaska Academy of Family Physicians Annual

Conference, Anchorage, Alaska

Presentation March 29, 2002, Moscow, Idaho

84. “Does Early Treatment Reduce Morbidity and Mortality in Asthma?”

Presentation June 7, 2001, at the 24th Annual Snake River Medical Forum,

Lewiston, Idaho

85. “Anti-IgE Therapy: A Novel Treatment for Asthma”

Presentation May 17, 2004, Butte, Montana

Presentation May 12, 2004, Moses Lake, Washington


Presentation October 7, 2001, Northwest Society of Allergy Nurses’ 14th

Educational Conference, Newport, Oregon

Presentation August 20, 2003, Tacoma, Washington

Presentation September 11, 2003, Airway Heights, Washington

Presentation September 23, 2003, Kennewick, Washington

Presentation September 25, 2003, Spokane, Washington

Presentation October 22, 2003, Billings, Montana

Presentation December 4, 2003, Walla Walla, Washington

Presentations February 23, 2004, Great Falls and Helena, Montana

Presentation March 31, 2005, Kellogg, Idaho

Presentation May 12, 2005, St. Maries, Idaho

Presentation July 11, 2005, Everett, Washington

Presentation December 7, 2005, Trinidad, California

86. “Anaphylaxis”

Presentation October 16, 2001, to regional physicians in Steilacomb, Wa.

87. “The Role of Long-Acting Beta 2 Agonists in Asthma Management”

Presentation October 24, 2001, to local physicians in Richland, Wa.



Presentation November 15,2001, to national investigator’s meeting in

Orlando, Florida—ACAAI physician survey.

89. “The Social and Physiologic Effects of Allergic Rhinitis”

Presentation February 23, 2002, Sandpoint, Idaho

Presentation April 13, 2002, Renton, Washington

Presentation April 24, 2002, Seattle, Washington

Presentation May 3, 2002, Sheridan, Wyoming

Presentation May 22, 2002, Seattle, Washington

Presentation May 29, 2002, Coeur d’Alene, Idaho

Presentation June 29, 2002, Anchorage, Alaska

Presentation December 11, 2002, Mountain Home, Idaho

90. “Patient Preference in Allergic Rhinitis”

Presentation March 23, 2002, to National Respiratory

Visiting Professor Program, Lake Louse, Alberta, Canada

National Teleconference Speaker: March 4, 5, 6, 12, 13, 18, 19, 20, 21, 25, 26

April 1, 3, 11, 17, 22, 23, 29; September 23, 24; October 1, 3, 24, 2002

91. “How to Differentiate Sinus from Migraine Headaches”

Presentation May 14, 2002, Seattle, Washington

Presentation May 21, 2002, Portland, Oregon

Presentation June 5, 2002, Seattle, Washington

Presentation July 16, 2002, Portland, Oregon

Presentation July 18, 2002, Salt Lake City, Utah

92. Co-Chair, Respiratory Speaker Academy Training Program,

December 13-15, 2002, Orlando, Florida

93. “The Role of Leukotriene Inhibitors in the Treatment of Allergic Rhinitis ”

Presentation May 5, 2004, Richland, Washington


Presentation April 19, 2004, Great Falls, Montana

Presentation April 13, 2004, Olympia, Washington


Presentation May 15, 2003, Kirkland, Washington

Presentation April 17, 2003, Modesto, California

Presentation April 16, 2003, Kennewick, Washington

Presentation March 26, 2003, Lewistown, Montana

Presentation March 25, 2003, Lewiston, Idaho

Presentation March 18, 2003, Hillsboro, Oregon

Presentation March 10, 2003, Moses Lake, Washington

Presentation March 4, 2003, Great Falls, Montana

Presentation February 26, 2003, Chelan, Washington

Presentation February 6, 2003, Portland, Oregon


.

94. “An Update of the Treatment of Allergic Rhinitis”

Presentation (RCM) May 8, 2004, Cleveland, Ohio

Presentation February 27, 2003, Deer Park, Washington

Presentation March 19, 2003, Cheney, Washington



National Teleconference Speaker: January 15, 30; February 12, 19;

March 5, 11, 12, 20, 24, 27; April 23, 30; May 7, 13, 2003

95. “Reactions to Remicaide”

Presentation May 5, 2003, Spokane, Washington

96. “How Should We Be Using Antibiotics? Resistance Issues”

Presentation at Primary Care Physicians’ Twentieth Annual Conference,

May 3, 2003, Spokane, Washington

97. “An Update on Allegra for Allergic Rhinitis”

Presentation March 1, 2003, Phoenix, Arizona

Presentation April 26, 2003, Pittsburgh, Pennsylvania

Presentation July 12, 2003, Travis, Michigan

98. “Ciclesonide: A Novel Oral Inhaled Corticosteriod for the Treatment of Asthma”

Presentation March 1, 2003, Phoenix, Arizona

Presentation April 26, 2003, Pittsburgh, Pennsylvania

Presentation July 12, 2003, Travis, Michigan

99. “The Role of Isomers in the Treatment of Asthma”

Presentation September 12, 2003, Coeur d’Alene, Idaho

100. “Allergic Rhinitis and Urticaria: Case Presentations”

Presentation September 18, 2003, Lewiston, Idaho

101. “The Association of Allergic Rhinitis and Asthma: Chronic Allergic Respiratory

Syndrome”

Plenary Session Presentation at the Third Balkan Congress of Allergy and

Clinical Immunology on October 13, 2003, Istanbul, Turkey

102. “The Role of Small Airways in Asthma Management”

Presentation May 25, 2004, Reno, Nevada

Presentation May 18, 2004, Benton County Medical Society, Pasco, Washington

Presentation February 4, 2004, Yakima, Washington

103. “Chronic Allergic Respiratory Syndrome”

Presentation March 16, 2004, Medical Grand Rounds,

Walla Walla, Washington


104, “The Role of Leukotriene Modifiers in the Treatment of Allergic Rhinitis and Asthma”

Presentation October 19, 2004, Honolulu, Hawaii

Presentation September 22, 2004, Eugene, Oregon

Presentation September 9, 2004, Newport, Washington

Presentation September 8, 2004, Great Falls, Montana

Presentation September 1, 2004, Tacoma, Washington

Presentation July 22, 2004, Silverdale, Washington

Presentation May 19, 2004, to University of Washington medical residents, Seattle, Wash


Presentation February 7, 2005, Yakima, Washington

Presentation March 24, 2005, Yakima, Washington

Presentation March 29, 2005, Federal Way, Washington

105. “New Treatments in the Management of Asthma”

Presentation October 2, 2004 in Spokane, Washington at the Washington State Medical

Association Annual Meeting

Presentation May 21, 2004 in Wenatchee, Washington at the Washington Academy of

Family Practice

106. “Allergic Rhinosinusitis”

Presentation September 21, 2004, at Medical Grand Rounds, Kennewick, Washington

Presentation August 26, 2004, Moscow, Idaho

Presentation June 4, 2004 in Sandpoint, Idaho

107. “Hymenoptera Hypersensitivity”

Plenary talk at Polish Allergy Society Meeting in Krakow, Poland on August 1, 2004

108. “Management of Respiratory Infections”

Presentations November 3, 2004, Odessa and Yakima, Washington

Presentation January 18, 2005, Whitefish, Montana

Presentation January 19, 2005, Medical Grand Rounds, Missoula, Mt.

Presentation April 20, 2005, Portland, Oregon

Presentations April 21, 2005, Billings, Mt. and Sheridan, Wyoming

Presentations July 19, 20, 2005, Helena, Montana

Presentations September 14, 2005, Moses Lake and Yakima, Wa.

Presentations October 13, 2005, Billings, Mt. and Sheridan, Wyoming

Presentation October 27, 2005, Richland, Washington

Presentation November 16, 2005, Coeur d’Alene, Idaho

Presentation December 20, 2005, Medical Grand Rounds, Kennewick, Wa.

109. “Allergies, Asthma, and Allergy Testing”.

Presentation April 14, 2005, Annual Meeting of American College of

Physicians, San Francisco, California

110. “Allergic Rhinitis: Looking Beyond Quality of Life”.

Presentation April 30, 2005, Portland, Oregon

Presentation June 3, 2005, Milwaukee, Wisconsin


111. “Mechanisms of Allergy and Asthma”.

Presentation September 10, 2005, Annual Meeting of Northwest

Society of Allergy Nurses, Gleneden Beach, Oregon

112. “Allergies, Asthma, and Allergy Testing"

Presentation June 6, 2006; 16 th International Meeting of Asthma, Allergy, and Immunology, Buenos Aires, Argentina.

113. “Association of Allergic Rhinitis and Asthma: Chronic Allergic Respiratory

Syndrome”.

Presentation June 6, 2006; 16 th International Meeting of Asthma, Allergy, and Immunology, Buenos Aires, Argentina.

114. “Hymenoptera Hypersensitivity”

Presentation October 29, 2007; 34 th Brazil Congress of Allergy and

Immunopathology, Salvador, Brazil.

115. “Will Pay for Performance Improve Allergy and Asthma Care?”

Presentation November 13, 2007; American College of Allergy, Asthma, and

Immunology, Dallas, Texas

116. “Anaphylaxis”

Presentations December 9 and 11, 2007; Annual Meeting of Hong Kong Allergy

Convention, Hong Kong and Xian, China

117. “Angioedema and Urticaria”

Presentations December 9 and 11, 2007; Annual Meeting of Hong Kong Allergy

Convention, Hong Kong and Xian, China

118. “Rhinitis Practice Parameter Update”

Presentation December 5, 2008; Jerusalem, Israel

119. “State of the College”

Presentation December 6, 2008; Jerusalem, Israel

March, 2009; Dubai

August 2009, Ecuador

September 2009, Georgia

November 2009; Miami, FL

120. “Improving the Quality of Life in patients with Severe Persistent Asthma”

Presentation March, 2009; Dubai

August 2009, Ecuador

September 2009, Georgia

November 2009; Miami, FL


121. “Improving Outcomes in Hereditary Angioedema Clinical Cases and Expert Opinion:

Individualization of Therapy” Presentation, November 2010, Phoenix, AZ

PHARMACEUTICAL STUDIES:

1. Asthma Study (Tilade, Fisons), Primary Investigator, summer 1993.

3.

2. Allergic Rhinitis Study (Rhinocort, Astra), Primary Investigator, summer 1994.

Asthma Study (Serevent, Glaxo 5001), Primary Investigator,

1994-1995.

6.

4.

5.

Sinusitis Study (Vantin, Upjohn), Primary Investigator,

1995-1997.

Asthma Study (MK-0476, Merck), Subinvestigator, 1994-1995.

Herpes Zoster Study (Famciclovir, Smith, Kline, Beecham),

Primary Investigator, 1995.

7. Asthma Study (Vanceril, Schering/Key), Primary Investigator, spring 1995.

8. Asthma Study (Powdered Salmeterol, Diskus, Glaxo 3011), Primary Investigator,

1995-1996.

9. Asthma Study (Intal, Fisons Corporation), Sub-investigator, 1995-1996.

10. Asthma Study (Pranlukast, Anti-leukotriene, SmithKline Beecham), Primary

Investigator, 1995-1996.

11. Asthma Study (Azmacort HFA-134a non-CFC propellant study, Rhone-Poulenc

Rorer), Primary Investigator, 1995-1996.

12. Asthma Study (Sepracor 051-024, R-Albuterol in the Reversal of Broncho- constriction and in the Management of Asthma, Phase III), Primary Investigator,

1996-1997.

13. Skin Testing (Evaluation of English Plantain Proposed Reference using the

SARAH Method, AF-95-001, Bayer Corporation), Primary Investigator,

1996.


14. Asthma Study, C96-137 (Placebo-Controlled Efficacy and Safety Study with

Long-Term Safety Evaluation of Mometasone Furoate Dry Powder in

Reducing Oral Steroid Requirements in Patients with Severe Asthma; Schering-

Plough, Phase III), Primary Investigator, 1996-1998.

15. Bronchitis Study (Acute Exacerbation of Chronic Bronchitis, Bay 12-8039,

Phase II, Bayer Corporation), Primary Investigator, 1996-1997.

16. Sinusitis Study (Acute Bacterial Maxillary Sinusitis, Bay 12-8039/Protocol

#D96-023, Phase II, Bayer Corporation), Primary Investigator, 1996-1999.

17. Bronchitis Study (Acute Bronchitis, M96-456, Phase III, Abbott Pharmaceuticals),

Primary Investigator, 1997.

18. Asthma Study (Pranlukast, Phase III, SkB, SB205312), Primary Investigator,

1996-97.

19. Asthma Study (Schering-Plough C-96-196, Phase III), Primary Investigator,

1997-1998.

20. COPD Study (SLGA-4021: A Comparison of Salmeterol Versus Theophylline versus Salmeterol Plus Theophylline in COPD Patients), Glaxo Wellcome, Inc.,

1997-1998.

21. Asthma Study (Spokane Epidemiologic Survey of Asthma, University of

Washington School of Medicine), Coinvestigator, 1997-1998.

22. Asthma Study (Schering-Plough C97-223, Phase III), Primary Investigator,

1997-1998.

23. Asthma Study (Schering-Plough C97-224, Phase III), Primary Investigator,

1997-1998.

24. Asthma Study (Zeneca Study No. 91 88IL/0150:0020, Phase III),

“A Multicenter Double-Blind Comparison of Zafirlukast With Placebo in

Pediatric Subjects with Mild-to-Moderate Asthma”, Primary Investigator,

1997-1998.

25. Chronic Bronchitis Study (Abbott, Phase III, M97-766), Primary Investigator,

1997-1998.

26. Asthma Study (Schering-Plough C-98-005-09, Pediatric, Phase III), Primary

Investigator, 1998-1999. “Placebo Controlled Efficacy and Safety Study of

Mometasone Furoate HFA-227 Metered Dose Inhaler in the Treatment of

Asthma in Children Previously Maintained on Inhaled Corticosteroids”


27. Asthma Study (Sepracor, Xopenex Solution, Phase IV), Primary Investigator,

1998-1999.

28. Reversible Obstructive Airways Disease Study (Novartis CGP25827A/073,

Formoterol, Phase III), Primary Investigator, 1998-1999. “Randomized

Parallel Group Open Label Multicentered Clinical Study Comparing the Safety,

Efficacy, Quality of Life, and Socioeconomic Variables of Twice Daily Formoterol

Powder (12 micrograms bid) to Twice Daily Salmeterol (50 micrograms bid)

Administered for Six Months to Adult Subjects with ROAD”

29. COPD Study (SmithKline Beecham, Ariflo, SB207499/039, Phase IIIA),

Primary Investigator, 1998-1999. “A 24-Week Double Blind Placebo Controlled

Randomized Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ariflo (15 mg bid) in Patients with COPD”

30. COPD Study (Glaxo FLTA3025, Phase III) Primary Investigator, 1998-1999.

“A Randomized Double-Blind Parallel-Group Comparative Trial of Inhaled

Fluticasone Proprionate Via the Diskus...in Patients with COPD”

31. Allergic Rhinitis/Seasonal Asthma Study (Schering-Plough P97-293, Phase IV),

Primary Investigator, 1998-1999.

32. Asthma Study, Named Patient (Astra, Pulmicort Respules, Study #04-3121,

Phase IV), Primary Investigator, 1998-1999.

33. Asthma Study, (SKB, CPMS Protocol: SB2445063-006, Phase IIA, IL-5),

Primary Investigator, 1998-1999. “A Multicenter, Double-Blind, Placebo-,

Controlled Randomized Study to Evaluate the Safety and Efficacy of SB240563 in

Patients with Moderate Asthma”

34. Asthma Study, (Glaxo Wellcome, SAS40021: Phase IV), Primary Investigator,

1999-2000. “A Randomized, Double-Blind, Double-Dummy, Parallel Group,

12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination

Product 50/100mcg BID Via the DISKUS Inhaler Versus Oral Montelukast

10mg QD in Adolescents and Adults with Persistent Asthma”

35. Influenza Study in Asthma and COPD, (Glaxo Wellcome, NAI30008), Primary

Investigator, 1999-2000. “A Double-Blind, Randomized, Placebo-Controlled,

Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of

Inhaled Zanamivir 10mg Administered Twice Daily for Five Days in the

Treatment of Influenza in Patients 12 Years or Over Diagnosed with Asthma or Chronic Obstructive Pulmonary Disease”

36. Seasonal Allergic Rhinitis Study (Schering-Plough Pol376-32). Primary

Investigator, summer/fall 2000. “Efficacy and Safety of Desloratadine 5 mg

Tablet in the Treatment of Subjects 12-17 Years of Age with Seasonal Allergic

Rhinitis”


37. Asthma Study (GlaxoSmithKline, FAP 30007, Phase III). Primary

Investigator, 2000-2001. “A Randomized, Double-Blind, Parallel

Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone

Propionate 88 mcg BID, 220 mcg BID, and 440 mcg BID versus

Placebo in Propellant GR 1066 42 X in Adolescent and Adult

Subjects with Asthma who are Maintained on Inhaled Corticosteriod

Therapy”

38. Asthma Study (GlaxoSmithKline FAP 30008, Phase III). Primary

Investigator, 2000-2001. “A Randomized Double-Blind, Parallel-Group,

Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88 mcg

BID, 220 mcg BID and 440 mcg BID versus Placebo in Propellant GR

106642 X in Adolescent and Adult Subjects with Asthma who are Maintained on Bronchodilator Therapy”

39. COPD Study (GlaxoSmithKline SMS40315, Phases III), Primary

Investigator, 2000-2001. “A Multi-Center, Randomized, Double-Blind,

Double-Dummy, Parallel Group, 8 Week Comparison of Salmeterol

Xinafoate Versus Salmeterol Xinafoate plus Ipratropium Bromide Versus

Placebo in Subjects with COPD”

40. Sinusitis Study (Abbott, ABT-773, Protocol MOO-225, Phase III). Primary

Investigator, 2000-2001. “Comparative Study of the Safety and Efficacy of

ABT-773 150 mg. QD versus 150 mg. BID for the Treatment of Acute

Bacterial Sinusitis”

41. Asthma Study, Pediatric (Aventis XRP1526B-341, Phase III). Primary

Investigator, 2001. “Double-Blind, Placebo-Controlled, Parallel-Group,

Multicenter, Efficacy, Safety and Dose Response Study of Ciclesonide Metered

Dose Inhaler 50 mcg/day, 100 mcg/day, and 200 mcg/day (Ex-Valve) Administered

Once Daily for 12 Weeks in the Treatment of Children with Persistent Asthma”

42. Asthma Study, Pediatric (Aventis XRP1526B-341 LT, Phase III). Primary

Investigator, 2001. “A Multicenter, Open-Label, One Year Long Term Safety

Study of Ciclesonide Metered Dose Inhaler 50 mcg/day to 200 mcg/day (ex-valve)

Administered once daily for the Treatment of Children with Persistent Asthma”

43. Asthma Study, Adolescents and Adults (Aventis 251526-321, Phase III). Primary

Investigator, 2001. “Double-Blind, Placebo-controlled, Parallel-group, Multicenter

Efficacy, Safety and Dose Response Study of Ciclesonide Metered Dose Inhaler

100 mcg/day, 200 mcg/day, and 400 mcg/day (ex-valve) Administered Once Daily for 12-Weeks in the Treatment of Mild to Moderate Persistent Asthma in

Adolescents and Adults”


44. Asthma Study (Aventis XRP1526B-326, Phase III). Primary Investigator,

December 2001. “A Multicenter, Open-label, Long-Term (1 year) Safety Study of

Ciclesonide 100 micrograms/day to 400 micrograms/day (Ex-Valve) Metered Dose

Inhaler Administered Once Daily For the Treatment of Mild to Moderate Persistent

Asthma in Adolescents and Adults.

45. COPD Study (GlaxoSmithKline, SCO30003, TORCH). Primary Investigator,

2001-2004. “A Multicentre, Randomized, Double-Blind, Parallel Group, Placebo-

Controlled Study to Investigate the Long-Term Effects of Salmeterol/Fluticasone

Propionate (Seretide/Viani/Advair) 50/500 mcg bd, Salmeterol 50 mcg bd and

Fluticasone Propionate 500 mcg bd, all Delivered Via the Diskus/Accuhaler

Inhaler, on the Survival of Subjects with COPD over 3 years of Treatment”

46. COPD Study (SmithKline Beecham, SB207499-168, Phase III). Subinvestigator,

2001-2002. “A Randomized, 12-week, Double-blind, Placebo-controlled,

Parallel-group Study to Evaluate the Safety and Tolerability of Ariflo (15 mg bid) in

Patients with Chronic Obstructive Pulmonary Disease (COPD).”

47. Asthma Study (Genentech, Q2143g, Phase III). Primary Investigator, 2001-2002.

“A Multicenter, Randomized, Controlled, Open-Label Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Subjects Already Treated With

Other Therapies (ALTO)”

48. Rhinitis Study (Merck, PAR 246). Primary Investigator, 2001-2002.

“A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-

Group Study Investigating the Clinical Effects of Montelukast in Patients

With Perennial Allergic Rhinitis (Protocol 246-00)”

49. Asthma Study (GlaxoSmithKline, SAS40036). Primary Investigator, 2001-2002.

“A Multi-center, Randomized, Double-Blind, Double-Dummy, Parallel Group,

16-Week Comparison of Asthma Control in Adolescents and Adults Receiving

Either Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50 mcg BID, Fluticasone Propionate DISKUS 100 mcg BID, Salmeterol Xinafoate

DISKUS 50mcg BID, or Oral Montelukast 10MG QD”

50. Asthma Study (Novartis, CFOR258D2307, Phase III). Primary Investigator. 2002.

“A randomized, multicenter, placebo-controlled parallel group study of four month’s duration per patient to evaluate the safety and efficacy of treatment with

24mcg b.i.d. and 12mcg b.i.d. formoterol, double-blind, and 12mcg b.i.d. formoterol with additional on-demand formoterol doses, open-label, in adolescent and adult patients with persistent stable asthma”

51. Asthma Study (Astra-Zeneca, SD-039-0726, Phase III). Primary Investigator, 2003-2004.

“A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-

Controlled Study of SYMBICORT pMDI Administered Once Daily in Adults and

Adolescents with Asthma – STEM”


52. Asthma Study (Sepracor, Protocol 051-355, Phase III). Primary Investigator, 2003.

“A Double-Blind, Randomized, Placebo- and Active-Controlled, Multicenter,

Parallel-Group Study Evaluating the Safety and Efficacy of 90 micrograms

Levalbuterol, 180 micrograms Racemic Albuterol and Placebo”

53. Asthma Study (Hoffmann-LaRoche, Protocol BA16631, Phase II). Primary Investigator,

2003-2004. “Dose-ranging Study of Ro 27-2441 in Patients With Persistent Asthma Not

Treated

With Inhaled Corticosteroids”

54. Asthma Study (Pharmacia/Pfizer, Protocol PDEAAS 1500-002, Phase III),. Primary

Investigator, 2003-2004. “A 24 Week, Double-Blind, Randomized, Placebo –Controlled

Clinical Trial to

Evaluate the Efficacy and Safety of Oral Roflumilast (250mcg or 500mcg) Daily in

Patients with Asthma”

55. COPD Study (Pharmacia, Protocol PDEACO-9287-001, Phase III). Primary Investigator,

2003-2004.

“A 24-Week, Placebo-Controlled, Randomized, Parallel Group Study

Comparing Roflumilast 500 mcg Daily vs. Placebo on Pulmonary Function and

Respiratory Symptoms in Patients with Chronic Obstructive Pulmonary Disease”

56. Asthma Study (Aventis, Protocol XRP1526B-3027, Phase III). Primary Investigator,

2004-2005. “A Multi-Center, Multinational, Randomized, Double-Blind, Parallel Group

Study of the Effects of Ciclesonide HFA-MDI 640 mcg/Day and Beclomethasone HFA-

MDI 640 mcg/Day on Lens Opacification in Adult Subjects with Moderate to Severe

Persistent Asthma”

57. COPD Study (GSK, Protocol SCO40041, Phase III), Primary Investigator, 2004-2007.

“A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of the Fluticasone Propionate/Salmeterol Combination Product 250/50 mcg BID via

DISKUS versus Salmeterol 50 mcg BID via DISKUS on Bone Mineral Density in

Subjects with Chronic Obstructive Pulmonary Disease (COPD).

58. Perennial Allergic Rhinitis Study (Altana, Protocol BY9010/M1-403, Phase III).

Primary Investigator, 2005. “A Randomized, Double-Blind, Placebo-Controlled,

Parallel-Group Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of

Ciclesonide Applied As a Nasal Spray at Three Dose Levels (200mcg, 100 mcg, or 25

,mcg once daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 6-11

Years of Age”

59. Sinusitis Study (Bayer, Protocol 100569, Phase IV). Primary Investigator 2004-2005.

“Prospective, Multicenter, Open, Uncontrolled Trial to Evaluate the Time to Bacterial eradication and key Symptom Relief in the treatment of Acute Bacterial Maxillary

Sinusitis with Moxifloxacin 400 mg QD”


60. COPD Study (GSK, Protocol SCO40043, Phase 3), Primary Investigator, 2004-2005.

“A Randomized, Double-Blind, Parallel-Grpi 52-week Study to Compare the Effect of the Fluticasone Propionate/Salmeterol DISKUS TM Combination Product 250/50mcg

BID with Salmeterol DISKUS 50 mcg BID on the Annual Rate of Moderate/Severe

Exacerbations in Subjects with Chronic obstructive Pulmonary Disease (COPD)”

61. Chronic Bronchitis Study (Aventis, Protocol HMR 3647A/4020, Phase IV), 2004-2005.

“An open-label, randomized, multi-center, clinical study to compare the effects of telithromycin, azithromycin and cefuroxime axetil on the penicillin or macrolide resistance of Streptococcus pneumoniac in patients with acute exacerbation of chronic bronchitis”

62. Seasonal Allergic Rhinitis Study (Alcon, Protocol C-04-20, Phase 3), Primary

Investigator, 2005. “Safety and Efficacy of Olopatadine Hydrochloride Nasal

Spray in Pediatric Patients”

63. Extract Injection Study (Hollister-Stier, HS-JT-OO-OO1A). Primary Investigator,

September 2000. “Comparison of the J-Tip Needleless Syringe to a Conventional

Syringe in the Administration of Allergic Extract”

64. Antigen Study (Hollister Stier, HS-AP-OO-OO1A). Primary Investigator, October

2000. “Quantitative Intradermal Procedure to Determine Relative Potency and

Compositional Differences Between AP(R) Dog and Regular Process Dog

Allergenic Extracts”

65. Antigen Study (Hollister Stier, Protocol HS-AG-OO-OO1R). Primary Investigator

November 2000 “Quantitative Procedure to Determine Relative Potency and

Compositional Differences Between Diafiltered Short Ragweed Allergenic Extract and Two Commercially Available Short Ragweed Allergenic Extracts”

66. Asthma Study (GlaxoSmithKline, SLGA 5011), (SMART). Primary Investigator, 2000.

“Salmeterol Multicenter Asthma Research Trial Study”.

67. Asthma Study (Genentech, Protocol Q2196n), (TENOR). Primary Investigator, 2000-

2003. An Observational Study of the Epidemiology and Natural History of Asthma:

Outcome and Treatment Regimens”.

68. Asthma Study (Genentech, Protocol Q2948g), (EXCELS). Primary Investigator, 2004-

2009. “An Epidemiological Study of Xolair (Omalizumab): Evaluating Clinical

Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma”.

69. Asthma Study (Novartis, Protocol #CIGE025AUS23, Phase lV), (CLUSTER). Primary

Investigator, 2006-2007. “A 26 –Week, Randomized, Double-Blind, Parallel-Group,

Placebo Controlled, Multi- Center Study to Evaluate the effect of Xolair on Improving the tolerability of specific Immuno-Therapy in Patients with at least Moderate Persistent

Allergic Asthma Inadequately Controlled with Inhaled Corticosteroids.”


70. Hereditary Angioedema Study (LEV Pharmaceuticals, LEVP2005-1, Phase III). Principal

Investigator, 2006-2007. “C-1 Inhibitor in Hereditary Angioedema Nanofiltration

Generation Evaluating Efficacy Trial”

71. Allergy Study (Kendle International, GrassMATAMPL301, Phase III). Principal

Investigator, 2007-2007. “Efficacy and Safety/Tolerability of Grass MATA MPL, a

Randomized, Placebo-Controlled, Double-Blind Study”.

72. Allergic Rhinitis (Sanofi-Aventis, XRG5029C/3503, Phase IIIa). Principal Investigator,

2007-2008. “A Randomized, Multi-center, Double-Blind, Placebo-Controlled, Parallel

Group Study of the 12 Month Effect of Treatment with Once Daily Triamcinolone

Acetonide (NASACORT AQ Nasal Spray 100ug) on the Growth Velocity of Children 3-9

Years of Age, with Perennial Allergic Rhinitis”.

73. Severe Disease to Assess Asthma Control, Allergies, Patient Outcomes and Treatment

Study. (CHARIOT). Retrospective Chart Review Study 2007

74. Combivent Study (Boehringer Ingelheim, 1012.56, (Phase 3). Sub Investigator, 2006 –

2008. “A comparison of ipratropium bromide/salbutasmol delivered by the Respimat inhaler to COMBIVENT Inhalation Aerosol and ipratropium bromide delivered by the

Respimat in a 12 week, double-blind, safety and efficacy study in adults with chronic obstructive pulmonary disease

75.

Crescendo Study (Sanofi Aventis, SR141716, (Phase 3). Sub Investigator 2005 – present. “Randomized, multinational, multi-center, double-blind, placebo-controlled, two-arm parallel group trial of rimonaqabant 20 mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors.”

76.

COPD/Inhaled Insulin, (Pfizer, A2171030, phase III). Sub Investigator 2006 – 2007.

“Efficacy and Safety of Inhaled Human Insulin (Exubera). Compared with Subcutaneous

Human Insulin in the Therapy of Adult Subjects with Type 1 or Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease. A One-Year Multi center, Randomized

Outpatient, Open-Label, Parallel Group Comparative Trial.”

77.

Asthma/Inhaled Insulin, (Pfizer, A2171028, phase III). Sub Investigator 2006 – 2007.

“Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared with Subcutaneous

Human Insulin in the Therapy of Adult Subjects with Type 1 or Type 2 Diabetes Mellitus and Chronic Asthma. A One Year Multi-center Randomized, Outpatient, Open-Label,

Parallel-Group Comparative Trial.”

78.

Osteoarthritis/Rheumatoid Arthritis, (Pfizer, A3191172, Phase IV) Sub Investigator

2006 – present. “A Randomized, Double-Blind, Parallel-Group Study of Cardiovascular

Safety in Osteoarthritis or Rheumatoid Arthritis Patients with or at High Risk for

Cardiovascular Disease comparing Celecoxib with Naproxen and Ibuprofen.”


79.

Pneumonia, (Enanta Pharmaceuticals, Inc., EDP420-05-006, phase IIa), Sub Investigator

2005 – 2006 “A Randomized, Double-Blinded, Parallel Group, Multi-Center study of

EDP-420 versus Telithromycin for the Treatment of Community Acquired Pneumonia.”

80. Diabetes, (Novartis, CLAF237A23119, Phase 3b), Sub Investigator 2006 – present. “A multi-center, randomized, open-label, active controlled, parallel arm study to compare the efficacy of 12 weeks of treatment with Vildagliptin 100 mg, qd to thiazolidinedione

(TZD) as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy in a community-based practice setting.”

81. Insomnia, (Takeda, 01-05-TL-375-069), Sub Investigator 2007 – present. “A

Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Demonstrate the Subjective Treatment Effects of Ramelteon on Sleep Using a Post Sleep

Questionnaire-Interactive Voice Response System (PSQ-IVRS) in an “At Home Setting” in an Adult Population with Chronic Insomnia.”

82. Gout, (TAP Pharmaceutical Products, Inc, F-GT06-153, Phase 3), Sub Investigator

2006 – present. “A Randomized, Multi-Center, Double-Blind, Allopurinol-Controlled

Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects with Gout.”

83. COPD (Glasko-Smith-Kline, SCO100250, phase ), Sub Investigator, 2007-2008. “A

Randomized, Double-Blind, Parallel-Group, 52-week Study to Compare the Effect of the

Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 bid with

Salmeterol DISKUS 50 mcg bid on the Annual Rate of Moderate/Severe Exacerbations in

Subjects with Chronic Obstructive Pulmonary Disease (COPD).”

84. Asthma (AstraZeneca, D5896C00025 phase ), Sub Investigator, 2006-2008, “A twoweek, Randomized, Double-Blind Study Assessing the Onset of Effect Questionnaire

(OEQ) Administered Pre-dose Versus Post-dose in Adult Subjects (≥18 years of age) with Mild to Moderate Asthma, Receiving SYMBICORT pMDI 80/4.5 ug x 2 Actuations

Twice Daily or Budesonide HFA pMDI 80 ug x 2 Actuations Twice Daily.”

85. Asthma (Genentech Q3662g, EXTRA phase ), Principal Investigator, 2006-2008, “A

Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled

High-Dose Inhaled Corticosteroids and Long-Acting Beta-Antagonists.”

86. Asthma (Schering-Plough, P04828), Principal Investigator, 2007-2008, “A Study of the

Therapeutic Equivalency of MF DPI 100 mcg and 200 mcg Inhalers in Corticosteroid-

Dependent Subjects with Moderate Asthma.”

87. Asthma (Boehringer Ingelheim, 1012.56), Sub Investigator, 2006-2008, “A Comparison of Ipratropium Bromide / Salbutamol Delivered by the Respimat Inhaler to Combivent

Inhalation Aerosol and Ipratropium Bromide Delivered by the Respimat.”


88. Conjunctivitis (Alcon, SMA-07-03, phase IV). After Market Research, 2007. “Pataday

Allergic Conjunctivitis Evaluation )PACE) Trial, a Multi-site, Open-Label Study of

Patient Perception of the Use of Olapatadine 0.2% with Patients who Previously used

Other Ocular Anti-Allergy Medication.”

89. COPD (Boehringer Ingelheim, 1205.14, phase ) Sub Investigator, 2007-2008. “A Multi-

National, Randomized, Double-Blind, Placebo and Activated-Controlled, Parallel Group

Efficacy and Safety Comparison over 24 weeks of Three Doses (50 ug, 100 ug, 200 ug) of

BEA 2180 to Tiotropium 5 ug and Placebo Delivered by the Respimat Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD).”

90. Pneumonia (Boehringer Ingelheim, 1205.14, phase ) Sub Investigator, 2007-2008. “ A

Prospective, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of

Faropenem Medoxomil 600 mg PO, BID for 10 days Versus Levofloxacin in the

Treatment of Community-Acquired Pneumonia.”

91. Asthma (Glasko-Smith-Kline, FFA109684), Primary Investigator. 2008 “A Randomized,

Double-Blind, Double Dummy, Placebo controlled, Parallel Group, Multicenter Dose

Ranging Study to Evaluate the Efficacy and Safety of Inhalation Powder Once Daily and

Fluticasone Propionate Inhalation Powder 500 mcg Twice Daily Compared with Placebo for 8 weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on a

Moderate Dose of ICS Therapy.”

92. Asthma (Glasko-Smith-Kline, FFA109685), Primary Investigator. 2008 “A Randomized,

Double-Blind, Double Dummy, Placebo Controlled, Parallel Group, Multicenter Dose


Fluticasone Propionate Inhalation Powder 250 mcg Twice Daily Compared with Placebo for 8 weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on a

Low Dose of ICS Therapy.”

93. Asthma(Glasko-Smith-Kline, FFA109687), Primary Investigator. 2008 “A Randomized,

Double-Blind, Double Dummy, Placebo Controlled, Parallel Group, Multicenter Dose


Fluticasone Propionate Inhalation Powder 100 mcg Twice Daily Compared with Placebo for 8 weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on

Non-Steroidal Asthma therapy.”

94. Ocular Safety. (Glasko-Smith-Kline, FFR110537), Primary Investigator. 2008. “A

Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter, Two-year

Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110 mcg in Adults and Adolescents 12 Years of Age and Older with Perennial Allergic

Rhinitis.”


95. Sublingual Immunotherapy (Schering Plough P05239-children, P05238-adults) Primary

Investigator. 2008-2009 “A Double-Blind, Randomized, Placebo-Controlled, Parallel-

Group Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy with SCH

697243 ( Phleum Pratense ) in Adults and Children with a History of Grass Pollen Induces

Rhinoconjunctivitis With or Without Asthma.”

96. Pneumonia. (Wyeth 6115A1-3000) Primary Investigator. 2009. “A Phase 3, Open-Label,

Single-Arm Trial Evaluating the Safety, Tolerability, and Reactogenicity of a 13-valent

Pneumococcal Conjugate Vaccine in Ambulatory Elderly Adults Aged 70 Years and

Older Who Received 1 Dose of 23-valent Pneumococcal Polysaccharide Vaccine at Least

5 Years Before Study Enrollment.”

97. COPD (Forest LAS-MD-36) Investigator. 2009. “Aclidinium Bromide (muscarinic antagonist) Inhaler at two Dosage Levels Administered to Patients with Moderate to

Severe COPD.”

98. COPD (GSK-HZC102871) Investigator. 2009. “52 week Efficacy and Safety Study to

Compare three Dosages of Fluticasone Furoate with a New LABA vs. New LABA Alone on the Annual Rate of Exacerbations in Subjects with COPD.”

99. Chronic Idiopathic Urticaria (Health Outcomes Solutions). Investigator. 2008-2009. “A

Qualitative Telephone Interview Study in Adult Patients with Chronic Idiopathic

Urticaria.”

100. Chronic Idiopathic Urticaria (Genentech Q4577g). Primary Investigator. 2009 “A Phase

II, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of

Xolair (Omalizumab) in Patients with Chronic Idiopathic Urticaria who Remain

Symptomatic with Antihistamine (H1).”

101. Asthma (Novartis CIGE025AUS33). Sub-Investigator. 2008-2009. “A 26-week

Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Effect of omalizumab on Markers of Asthma Impairment in Patients with Persistent Allergic

Asthma.”

102. Hereditary Angioedema (ViroPharma 0624-400) Primary Investigator. 2009-2010. “A

Phase IV Study to Evaluate the Safety and Effect of Escalating Doses of Cinryze (C1 inhibitor [Human]) as Prophylactic Therapy in Subjects with Inadequately Controlled

Hereditary Angioedema Attacks.”

103. Asthma (Molly) Phase II trial. Primary Investigator. 2009-2010. “A Phase II,

Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate

Lebrikizumab (MILR1444A) in Adult patients With Asthma Who Are Not Taking

Inhaled Corticosteroids .”

104.

Acute H1N1 Tamiflu Phase IV trial. Primary Investigator. 2009-2010. “A Randomized,

Multicenter Trial of Oseltamivir Doses of 75 mg for 5 or 10 Days in Influenza Patients with pandemic (H1N1) 2009.”


105. COPD Phase III trial. Sub-Investigator. 2009-2010. “A 52-week Efficacy and Safety

Study to Compare the Effect of Three Dosage Strengths of Fluticasone

Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of

Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD).”

106. COPD Phase III trial. Sub-Investigator. 2009-2010. “Phase III, One-Year, randomized,

Open-label Safety and Patient Acceptability Study of Combivent Respimat (ipatropium bromide and albuterol sulfate) (20/100 mcg) Inhalation Spray in Comparison to

Combivent Inhalation Aerosol (36/206 mcg) and the Free Combination of Atrovent HFA

(ipatropium bromide HFA) Inhalation Aerosol (34 mcg) and Albuterol HFA Inhalation

Aerosol (180 mcg) in Adults with Chronic Obstructive Pulmonary Disease (COPD).”

107. Perennial Allergic Rhinitis (PAR) Phase III trial. Primary Investigator 2009-2010.

“Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of

MP03-36 (0.15% solution) and MP03-33 (0.10% solution) in Children Ages ≥6 to <12 with Perennial Allergic Rhinitis.”

108. Hereditary Angioedema (ViroPharma 0624-200) Phase II trial. Primary Investigator.

2010-2011. “An open-label, multiple-dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze™ in adolescents and adults with hereditary angioedema (Protocol 0624-200).”


109. Pediatric Asthma. (Astra-Zeneca AB D589GC00001) Primary Investigator. 2010. “A

Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 μg bid with placebo: a 6-week efficacy and safety study in children aged 6 to <12 years with asthma.”

110. Allergic Conjunctivitis (ISTA S00041) Phase II trial. Primary Investigator. 2010. “A randomized, double-masked, placebo-controlled, parallel group confirmatory natural exposure study of the safety and effectiveness of Bepreve (bepotastine besilate ophthalmic solution) 1.5% for the treatment of seasonal allergic conjunctivitis associated with nasal allergy symptoms.”

111. COPD. Sub Investigator. 2010. “A Randomized, Double-Blind, Parallel Group,

Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination

Product 250/50mcg BID (Advair Diskus) in Comparison to Salmeterol 50 mcg BID

(Serevent Diskus) on the Rate of Exacerbations of Chronic Obstructive Pulmonary

Disease (COPD) Following Hospitalizations.”

112. COPD. (Boerhinger Ingelheim) Sub-Investigator. 2010. A COPD study comparing

Tiotropium handihaler vs. Tiotropium Respimat.

113. Asthma (Biota) Primary Investigator. 2010. “A Phase 2 Multicenter, Randomized,

Double-Blinded, Placebo-Controlled, Study of BTA798 in Asthmatic Adults with

Symptomatic Human Rhinovirus Infection.”

114. CIU (Genentech) Primary Investigator. 2011. “A Phase III, multicenter randomized, double blind, dose ranging placebo controlled study to evaluate the efficacy response duration and safety of Xolair in patients with chronic idiopathic urticaria who remain symptomatic despite antihistamine treatment.”

115. Hereditary Angioedema (ViroPharma). Primary Investigator. 2011. “Open label single dose study to evaluate the response and pharmacokinetics/pharmacodynamics of different doses of Cinryze for treatment of acute Angioedema attacks in children less than 12 years of age with hereditary Angioedema.”


REFERENCES:

Henry N. Claman, M.D., Professor, Division of Allergy and Clinical

Immunology, University of Colorado Medical Center, 4200

East Ninth Avenue, Denver, Colorado 80220.

Patrick O. Tennican, M.D., Associate Professor of Medicine, former head of Internal Medicine Residency Program, Sacred Heart

Medical Center, West 105 Eighth Avenue, Spokane,

Washington, 99204.

Richard B. Byrd, M.D., Clinical Associate Professor of Medicine,

University of Washington, Department of Medicine, Rockwood

Clinic, East 400 Fifth Avenue, Spokane, Washington 99202.


Richard - Premier Clinical Research

Related documents

Add this document to collection(s)

Add this document to saved

Suggest us how to improve StudyLib